Forodesine hydrochloride clinical trials
A product of Forodesine; its studies count on that page too.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How each study uses forodesine hydrochloride is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Forodesine
Studies
Open first, then newest update. How each study uses forodesine hydrochloride is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma PatientsCompletedPhase 1/2Mundipharma K.K.NCT01776411Written as forodesine hydrochlorideHow we know
- Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell MalignanciesCompletedPhase 1Mundipharma K.K.NCT00823355Written as forodesine hydrochlorideHow we know
- Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell LymphomaCompletedPhase 1BioCryst PharmaceuticalsNCT00098332Written as forodesine hydrochlorideHow we know
- BCX-1777 in Treating Patients With Refractory CancerCompletedPhase 1BioCryst PharmaceuticalsNCT00073944Written as forodesine hydrochlorideHow we know
- BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell LymphomaCompletedPhase 1/2BioCryst PharmaceuticalsNCT00061880Written as forodesine hydrochlorideHow we know
- Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2BioCryst PharmaceuticalsNCT00289549Written as forodesine hydrochloride (BCX-1777)How we know
- Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2BioCryst PharmaceuticalsNCT00640523Written as forodesine HClHow we know
- Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment RegimensTerminatedPhase 2BioCryst PharmaceuticalsNCT00419081Written as Forodesine Hydrochloride Capsules (100 mg)How we know
- Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic LeukemiaCompletedPhase 1/2BioCryst PharmaceuticalsNCT00289562Written as forodesine hydrochloride (BCX-1777)How we know
- Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell LeukemiaCompletedPhase 2BioCryst PharmaceuticalsNCT00095381Written as forodesine hydrochloride (BCX-1777)How we know
Codes
What other systems call forodesine hydrochloride · ClinicalTrials.gg INT015321
- Wikidata Q27265452forodesine hydrochlorideOne source Wikidata
- NCI Thesaurus C26655Forodesine HydrochlorideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27265452 | forodesine hydrochloride | One source Wikidata |
| NCI Thesaurus | C26655 | Forodesine Hydrochloride | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.